Hypophysitis with Rapid Onset of Neurological Symptoms and Pituitary Mass Effect

When hypophysitis presents acutely with neurological deterioration driven by an enlarging pituitary gland, prompt recognition and a structured treatment approach are critical.

Clinical Scenario Rapid onset of neurological symptoms with mass effects arising from pituitary enlargement — a presentation that requires timely immunosuppressive intervention to reduce the compressive burden.

Treatment Approach (overview only) First-line management centres on immunosuppressive therapy. A glucocorticoid-based regimen is the established starting point, though the complete sequencing, agent selection, and adjustments over time go beyond what can be summarised here.

Full regimen detail — including agent choice, titration schedule, and monitoring criteria — is available in the structured protocol.

Instant Access to Structured Evidence-Based Regimens

References

Immunosuppressive therapy is utilized for patients with rapid onset of neurological symptoms and mass effects due to pituitary enlargement.

Glucocorticoids are the first-line immunosuppressive agents for the treatment of AHy.

Various forms of glucocorticoids (prednisone, methylprednisone, or dexamethasone) have been utilized in the treatment of hypophysitis, either as monotherapy or in combination with other immunosuppressive agents.

For glucocorticoid treatment of hypophysitis in general, after an initial high dose treatment (1mg/kg/day of prednisone or its equivalent), glucocorticoids are tapered over several weeks to months, and the duration of treatment is guided by the clinical response.

DOI: 10.1016/j.beem.2019.101371

View source ↗